Stem Cell Factor Antibody: Effective Manipulation of Antihormonal Therapy in Resistant Human Breast Cancer In Vitro. by Arif, Khalid et al.
ABSTRACT
Tamoxifen is the most commonly used drug in the treatment of breast cancer via blocking the estrogen receptor pathway. 
However, the use of Tamoxifen is limited by intrinsic and acquired resistance, which may be associated with the de-regulation 
of the kinase protein expression or an increase in multiple drug resistance (MDR) expression. Two breast cancer cell lines, wild 
type MCF7 WT (sensitive, i.e., ER+) and MDA-MB-231 (resistant, i.e., ER-), were used. Expression of P-glycoprotein (Pgp) 
was measured, the cells were treated with 4- hydroxy tamoxifen in the presence or absence of anti-stem cell factor, apoptosis 
protein (Annexin V) was measured and Influx/efflux rates were monitored by using Technetium99m methoxyisobutylisonitrile 
(99m Tc-Sestamibi-MIBI) at different time intervals. Results showed positive expression of AnnexinV in MDA-MB-231 and 
MCF7/WT, and the effect of blocking of the stem cell factor showed an increase in the drug accumulation within the MDA-
MB-231 cell line. In conclusion, this study showed that the anti-stem cell factor enhances the effectiveness of antihormonal 
therapies determined by 99m Tc-MIBI. These findings may have implications for the use of anti-stem cell factor with anti-
hormonal therapy in ER-negative breast cancer in order to overcome drug resistance and improve the outcome. 
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INTRODUCTION
Breast cancer is the most commonly diagnosed disease and the 
leading cause of cancer death in women worldwide.1 Tamoxifen 
is still the therapy of choice for ER+ breast cancer. However, 
over 30% of breast cancer patients with ER+ fail to respond 
to tamoxifen, whereas the responding patients may finally 
progress to a resistant phenotype.2,3 
Despite the significant improvements in cancer treatment, 
resistance to therapeutic agents still represents a significant 
issue for optimal clinical management, partially due to the 
decrease in intracellular drug accumulation, i.e., increase 
the efflux rate.4,5 In breast cancer, a significant correlation 
was indicated between intercellular drug accumulation 
and acquired resistance to tamoxifen. Studies suggested an 
association between the presence of P-glycoprotein (Pgp) and 
ineffective therapeutic medication resulting in poor prognosis. 
Therefore, Pgp expression might play a role in tamoxifen 
resistance.6-8
On the other hand, Previous studies showed evidences 
of the role of the signaling transduction pathways such as 
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mitogen-activated protein kinase (MAPK), c-Jun NH2-
terminal kinase (JNK), p38, cyclic adenosine monophosphate-
dependent protein kinase, phosphatidylinositol 3-kinase and 
protein kinase C signaling pathways in the regulation of the 
ATP-binding cassette (ABC) transporters.9 The ABC proteins 
are part of the largest family of transmembrane proteins. 
These proteins function as energy-dependent and transport a 
variety of molecules/substrates across cellular membranes.10 
The expression of these transport proteins is implicated in 
pumping the drugs out of the cells, which prevents intracellular 
anticancer drug accumulation. This drug accumulation 
causes the development of multiple drug resistance (MDR), 
which is considered as one of the cellular pathways involved 
in resistance to anticancer drugs. These protein transporters 
include ABCB1 (P-glycoprotein), ABCC1 (MRP1), ABCC2 
(MRP2), ABCC4 (MRP4), ABCG2 (BCRP) and the lung 
resistance protein (LRP).11,12
To provide the basis for more effective combined molecular/ 
endocrine therapy regimen in breast cancer patients, many 
efforts have been made for better understanding of tamoxifen 
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resistance mechanism in relation to ER expression, signal 
transduction pathway and co-regulatory proteins.13 Therefore, 
it is become necessary to switch to new treatment regimens to 
overcome MDR phenotype and increase drug accumulation 
i.e., inhibit drug eff lux rate to sensitize cancer cells to 
therapeutic agents.14 
C-kit (CD-117) is a proto-oncogene trans-membrane 
tyrosine kinase receptor (KIT), mainly found express in 
primitive haematopoietic cells, mast cells, melanocytes, and 
breast glandular epithelial cells, and is detected in the testicular 
and ovarian interstitial cells.15-17 
Stem cell factor (SCF), which also known as (Kit Ligand- 
KL, mast cell growth factor-MCGF and steel factor -SLF), is 
a haematopoietic cytokine present in both soluble and trans-
membrane forms. SCF has a wide range of biological activities 
in both normal and malignant tissues; it acts as a growth factor 
and regulates proliferation and differentiation.18,19
The binding of the SCF and Kit induces receptor 
dimerisation, resulting in enhancement of the tyrosine–
kinase activity and inducing signal transduction, which leads 
to biological activities such as cell apoptosis, proliferation, 
differentiation, adhesion, and motility.20,21 Ulivi and colleagues 
indicated a high expression of C-Kit/CSF in invasive breast 
cancer compared with the expression in normal breast cancer.22 
Blocking of SCF using anti stem cell factor (ASCF) enhanced 
the response to Adriamycin drug resulting in apoptosis of the 
leukaemia cell line.23
From therapeutic perspective, the study of the c-Kit/
CSF signaling pathway in relation to Pgp function becomes 
necessary for the development of targeted therapies to reduce 
drug efflux rate and to overcome resistance phenomena in 
diseases such as breast cancer 
Therefore, the goal of the present study was to enhance 
tamoxifen efficacy in ER-negative breast tumors using stem 
cell factor-antibody (anti-SCF). 
MATERIALS AND METHODS:
All the used reagents in this study were obtained from Sigma 
Aldrich, UK unless stated. All used cells were undergone 
between 15−20 passages. Cells were incubated whenever 
mention at 37°C in air/5% CO2 incubator, unless stated.
Cell Culture and Growth 
Tamoxifen sensitive cell line MCF7/WT and ER-negative 
MDA-MB-231 cell line obtained from the European type 
culture collection (ECACC). Cells were grown in complete 
tissue culture medium consisting of Iscove’s Modified 
Dulbecco’s Medium, IMDM supplemented with an antibiotic 
solution (100 units/ ml of penicillin, and 0.1 mg/ml of 
streptomycin) and 10% fetal calf serum (FCS), and placed in 
the incubator.
Flow Cytometric Analyses for ATP-binding cassette 
Transporter
From each cell line (1×106 cells/mL), cells were fixed in 1 ml 
of ice-cold methanol, permeablized using 100 µL of 0.1% 
triton –X100 in PBS, solution. The cells were labeled with 
P--glycoprotein (Pgp) monoclonal antibody (Santa Cruz 
Biotechnology, Inc., USA) and diluted in permeabilized 
solution (at a final concentration according to the manufacture’s 
recommendation) Finally the cells were incubated with 
fluorochrome-labeled secondary antibody, which had been 
prepared in 3% BSA/PBS according to the manufacture’s 
recommendation and cells were incubated at 4ºC in the dark 
for 30 minutes, then cell were washed three times according 
to the washing procedure and resuspended in ice-cold PBS, 
3% BSA and immediately analyzed using flow cytometry. 
(Beckman Coulter Diagnostics, UK).
Apoptosis Assessment 
Cell apoptosis was detected by staining with FITC-Annexin V. 
Cells lines were seeded in 25 cm2 tissue culture flasks in the 
incubator. After 24 hours, the cells were treated with anti stem 
cell factor (ASCF) and/or stem cell factor (SCF) in combination 
with 4-OH at 0.4 ug/mL, 100 units/ml and 17.5 uM respectively, 
and were incubated again for 48 hours. Quantitative expression 
of Annexin V was measured using Annixin V Elisa kit 
(Abnova-Taiwan), according to the manufacturer’s instructions.
99mTc-Sestamibi (MIBI) accumulation
The cultured cells were harvested and re-suspended at a 
concentration of 1×106 cells/ml in fresh medium and were 
incubated for 2 hours with ASCF and/or 4-OHT. The 99mTc-
Sestamibi (MIBI) experimental protocol was previously 
reported, briefly; single-cell suspensions at 106 cells per ml 
incubated with stirring in a 37°C water bath for 5 min to allow 
equilibration24 (Muzzammil et al., 2001). 99mTc-sestamibi 
cardio lite kit (IBA molecular, UK was added at a final 
concentration of 0.5 MBq/mL, samples were taken after at 0, 
30, 60, and 90 min. a. duplicate aliquots of 200 were removed 
from each tube and transferred to 5 -ml microcentrifuge tubes 
containing 800 ice-cold PBS and centrifuged at 14000 g for 
2 min. The supernatant was aspirated, and the cell pellet was 
washed with 1 mL ice-cold PBS, the pellet was assayed in 
duplicate for radioactivity using a gamma counter (Wizard2-
Perkinelmir.UK). The accumulation ratio was calculated, the 
ratio of radioactivity inside the cell to that outside (in/out).
Statistical analysis
Analyses were performed using the statistical analysis system 
IBM SPSS. P-values were determined using one and two way 
ANOVA. The data were presented as mean + standard error 
(SE) with a value of p < 0.05 were considered to be statistically 
significant and p < 0.01 as a highly significant.
RESULTS 
P-glycoprotein (Pgp) expression
Cell surface P-glycoprotein expression was detected by flow 
cytometric analysis. Cell surface P-glycoprotein staining 
was positive in the MDA-MB-231 cell line. However, this 
expression was minimal or absent in MCF-7/WT. These results 
indicated that the drug expulsion mechanism is relatively active 
in the ER-negative breast cancer cells and not in the ER-positive 
breast cancer cell line (control).
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Annexin V and SCF neutralization 
The effects of ASCF with or without 4-OHT on inducing 
apoptosis were determined via quantitative assessing of 
annexin V expression using ELISA. A significant expression 
of annexin V was indicated in MDA-MB-231and ER-positive 
MCF7/WT cell lines after treating the cells with ASCF and 
4-OHT (Figure 2). 
Technetium (99mTc) sestamibi (MIBI) 
The specificity of Tc99m for ABC transport assays was 
performed in the two breast cell lines MCF7/WT, MDA-
MB-231, cells incubated with ASCF alone and with 4-OHT. 
The effect of the ASCF on MDA-MB-231increasing the 
accumulation was significant; when the cells incubated with 
both ASCF and tamoxifen, the accumulation increased with 
time (p < 0.05), Figure (4). On the other hand, the high rate 
of the drug accumulation hasn’t affected by ASCF in the 
ER-positive MCF7/WT, shown in Figure 3.
DISCUSSION
Most of the studies suggest that the mode of action of tamoxifen 
is mediated by competitive inhibition of estrogen binding to 
ER.25 However, some studies showed that tamoxifen could 
mediate its effect vie ER independent mechanism, involving 
molecular, such as protein kinase c, TGFβ, and MAPKs.26
Therefore, testing the new and more specific molecular-
targeted therapeutic approaches in ER- breast cancer cells can 
offer a new concept for a more efficient combined molecular/
endocrine therapy regimen and may improve the treatment 
outcome.
It is well-documented fact that the presence of multidrug 
resistance protein (Pgp) the present study and despite 
differences in the presence and absence of ER expression, 
in MCF7/WT and MDA-MB-231 cells, which is inversely 
correlated with the presence of multidrug resistance protein 
(Pgp) as shown in Figure 1, results shows the ability of the 
ASCF to sensitize MDA-MB-231 cells to the anti-proliferative 
effects of tamoxifen and an increase in the drug accumulation 
in response to tamoxifen when were treated with a combination 
of ASCF and 4-OHT, Figures 2, 3 and 4.27
This observation may be explained by the role of c-Kit in 
the downstream signaling molecules through an interaction 
with stem cell factor (SCF), this interaction could play an 
Figure 1: The breast cancer cell lines used for indirect 
immunophenotyping of Pgp using flow cytometery. (a) 
Immunophentotyping of Pgp showing (<1%) in MCF/WT. (b) 
Immunophentotyping of Pgp showing (24.9%) in MDA-MB-231.
Figure 2: Effect of ASCF and SCF on Annexin V expression in the 
breast cancer cell lines (MCF/WT, and MDA-MB-231). All the cells 
were treated with 4-OHT alone and with ASCF. Results (n=3) are 
expressed as the mean value, ±SE. * p < 0.05.
Figure 3: Drug accumulation rate (In/out rate) for MCF7/WT cells 
treated with anti stem cell factors and incubated with 4-OHT. Data 
represent the mean value from three independent experiments (n=3) 
±SE and incubated with 4-OHT. Data represent the mean value from 
three independent experiments (n=3) ±SE.
Figure 4: Drug accumulation rate (influx/efflux rate) for MDA-MB-231 
cells treated with anti stem cell factors and incubated with 4-OHT. Data 
represent the mean value from three independent experiments (n=3) 
±SE.
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oncogenic role via regulating cell proliferation, anti-apoptosis, 
tumor reoccurrence and metastasis, which subsequently lead 
to an independent stimulation of the cellular functions.28,29
The importance of c-kit and its ligand, stem cell factor 
in the enhancement of proliferation and invasion via the 
phosphatidylinositol-3-kinase (PI3K)/Akt pathway, has been 
demonstrated in c-Kit positive colorectal cancer.30 Also, 
the stem cell factor is known as a tumor-derived factor, and 
previous studies have observed the expression of SCF and its 
receptor c-Kit in breast cancer.22
Nevertheless, ASCF elevation of apoptosis in MDA-MB-
231 is in agreement with the role of c-Kit and SCF in activating 
the transduction signaling cascade and the effects of these 
signaling cascades on ER phosphorylation as an independent 
mechanism of action in tamoxifen-resistant breast cancer.31-34 
Furthermore, it is well documented that SCF activates Erk1/2 
and p38 mitogen-activated protein kinase (MAPK) and that 
the blocking of SCF might lead to a reduction MAPK activity, 
and that might explain the growth inhibition.35
In the present study, the effect of ASCF in enhancing the 
response of tamoxifen was carried out via determining the 
expression of annexin V using ELISA. A significant result 
(p < 0.005) was indicated when MDA-MB-231 and MCF/WT 
cells were treated with a combination of ASCF and 4-OHT. 
Cumulatively, these data suggest that ASCF might enhance 
the response to tamoxifen in ER-negative tamoxifen-resistant 
breast cancer (ER-) and via involvement in the signaling 
cascade., which is in agreement with the previously published 
study of overcoming resistance to endocrine therapy and 
enhancing apoptosis by blocking of the c-kit and inhibition of 
signal transduction.36,37
The results from this study indicated that SCF neutralization 
could play a significant role in reducing the growth rate in 
MDA-MB-231 compared with MCF7/WT. Results from 
the present study are in agreement with previous studies 
on different tumor types such as pancreatic cancers and 
melanoma.38,30
For any cancer therapy, treatment efficiency determined 
by the delivery of high doses of the drug to tumor sites at the 
present study, the effects of the ASCF on the drug accumulation 
were evaluated using technetium 99mTc sestamibi uptake rate. 
Results showed a significant increases in influx/efflux rate in 
the MDA-MB-23 cell line, as shown in Figure 4 when treated 
with ASCF, also an increase of the uptake was noticed in the 
control cell lines, but to a lesser (non-significant) degree., this 
is indicating a potential role of the ATP-binding cassette (ABC) 
protein in drug resistance.39,40
Interestingly, our study demonstrated that the inhibition 
of the stem cell factor associated with an improved tumor 
drug uptake and a concomitantly enhanced therapeutic effect 
of the tamoxifen, this has been noticed in the increasing of 
99mTc-MIBI uptake, which is predicting the tumor response 
to the drug.41
These data suggest that the interference with SCF/c-Kit 
loop could be novel approaches to address tamoxifen resistance 
phenomena in the clinical management of breast cancer and to 
consider the pharmacologic utilization of both ER-dependent 
and ER-independent antitumor activities of tamoxifen and to 
avoid the multi drugs resistance development. Also, in this 
study, for the first time 99mTc-MIBI technique has been used 
to predict the drug uptake before and after the blocking of SCF 
in the breast cancer cell line.42,43
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